Hypersomnia

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
1
FlumazenilPhase 1/21 trial
Active Trials
NCT01183312Completed10Est. Jan 2012
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
Sleep studyN/A1 trial
Active Trials
NCT05850676Recruiting45Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsFlumazenil
Jazz PharmaceuticalsSleep study

Clinical Trials (2)

Total enrollment: 55 patients across 2 trials

Flumazenil for the Treatment of Primary Hypersomnia

Start: Sep 2010Est. completion: Jan 201210 patients
Phase 1/2Completed

Disentangling the Role of Depression in Hypersomnia

Start: Aug 2023Est. completion: Jun 202645 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 55 patients
2 companies competing in this space